Compare JFIN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.5M | 194.8M |
| IPO Year | 2018 | 2013 |
| Metric | JFIN | KPTI |
|---|---|---|
| Price | $4.05 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 75.3K | ★ 426.0K |
| Earning Date | 06-03-2026 | 05-04-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $3.70 | $3.65 |
| 52 Week High | $18.70 | $10.99 |
| Indicator | JFIN | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 58.40 |
| Support Level | $3.80 | $5.43 |
| Resistance Level | $4.54 | $9.58 |
| Average True Range (ATR) | 0.23 | 0.76 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 36.98 | 62.00 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).